Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MoST alectinib substudy for ALK-altered cancers
ACTRN12621000312842Phase 2Completed
- Sponsor
- University of Sydney
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alectinib in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms, sponsored by University of Sydney. Primary endpoints: Composite primary endpoint for metastatic NSCLC and Composite primary endpoint for other cancers. Started Sep 2021; status: completed.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on ACTRN12621000312842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000312842.